scispace - formally typeset
A

Antonio Craxì

Researcher at University of Palermo

Publications -  699
Citations -  44773

Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.

Papers
More filters
Journal ArticleDOI

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Sarah Blach, +221 more
TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑

TL;DR: The EASL CPGs on the management of HCV infection will be updated on a regular basis upon approval of additional novel therapies, and will apply to therapies that are approved at the time of their publication.
Journal ArticleDOI

Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

TL;DR: In patients with chronic hepatitis C who relapse after treatment withinterferon, therapy with interferon and oral ribavirin results in higher rates of sustained virologic, biochemical, and histologic response than treatment withInterferon alone.
Journal ArticleDOI

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Devin Razavi-Shearer, +195 more
TL;DR: The estimate of HBV prevalence in 2016 differs from previous studies, potentially because it took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time.